Cipla gets 8 observations from USFDA for Kurkumbh plant
Updated : March 31, 2019 10:33 PM IST
The company has also received 10 observations pertaining to a product-specific pre-approval (PAI) from the same plant, Cipla said in a BSE filing.
"These observations are both product specific and GMP observations related to the manufacturing and quality processes," the company said.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more